ETV6 and small cell lung carcinoma: ETV6‐NTRK3 fusion was detected in 1.6% (2/122) of SCLC, which was relatively rare, but may suggest a response to pan‐NTRK as well as ALK and ROS1 tyrosine kinase inhibitors.